These results demonstrated that the chronic administration of eritoran successfully suppressed the hepatic TLR4 signaling pathway by downregulating the MyD88 expression, NF-κB p65 nuclear translocation and phosphorylation of p38 and JNK in a NASH mouse model. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatohepatitis.